01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
On June 26, 2019, the U.S. District Court for the Southern District of New York in Mahmoud Latif v. ...
Read More >
It seems that it is impossible to talk to any fund today without learning that a SPAC is planned or ...
Read More >
Washington’s Department of Labor and Industries just decided to substantially raise the state’s sa...
Read More >
News that multiple cases of the newly-identified 2019 Novel Coronavirus have reached the United Stat...
Read More >
The COVID-19 pandemic is causing disruption to a wide range of industries and construction in the he...
Read More >
With the future of the EEOC’s pay data collection efforts unclear, California’s effort to legislat...
Read More >